RecruitingNot ApplicableNCT04312399

Hormone Replacement Trial Against ALzheimers' Disease

Sponsor

University Hospital, Ghent

Enrollment

600 participants

Start Date

Apr 17, 2018

Study Type

INTERVENTIONAL

Conditions

Alzheimer Disease Postmenopausal Symptoms

Summary

The influence of postmenopausal hormone treatment on dementia is not clear. Dysfunctions in the metabolism of amyloid in the disease of Alzheimer result in an elevated presence of degradation products in cerebrospinal fluid. The degradation products in blood will be analysed during the trial, to get better insight in menopause and the start of hormonal therapy. Postmenopausal women with and without history of breast cancer will be recruited for the trial.

Eligibility

Sex: FEMALEMin Age: 40 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether hormone replacement therapy (HRT) — estrogen-based medication — can reduce the risk of Alzheimer's disease in postmenopausal women. Researchers believe estrogen may protect the brain during the years right after menopause. **You may be eligible if...** - You are a postmenopausal woman - You are between 40 and 65 years old - You entered menopause less than 10 years ago **You may NOT be eligible if...** - You have been postmenopausal for more than 10 years - You have thyroid problems - You have high blood pressure (hypertension) - You have a history of psychiatric conditions - You have a history of alcohol or drug misuse - You have had neurological symptoms affecting thinking or memory Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.